← All trials
NCT04161430
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 20, 2020
- Primary completion
- Apr 27, 2024
- Completion date
- Jun 28, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 750
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shijiazhuang Pharma Group (CSPC)Lead sponsor
- Shijiazhuang Pharma Group (CSPC)Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.